Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemia | Loisel et al. Journal of Hematology Oncology 2010 3 49 http content 3 1 49 JOURNAL OF HEMATOLOGY ONCOLOGY LETTER TO THE EDITOR Open Access Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemia Séverine Loisel1 Karine Le Ster2 Michèle Meyer3 Christian Berthou1 2 Pierre Youinou1 2 Jean-Pierre Kolb4 5 6 Christian Billard4 5 6 Abstract Background We previously reported that allanxanthone C and macluraxanthone two xanthones purified from Guttiferae trees display in vitro antiproliferative and proapoptotic activities in leukemic cells from chronic lymphocytic leukemia CLL and leukemia B cell lines. Results Here we investigated the in vivo therapeutic effects of the two xanthones in a xenograft murine model of human CLL developed by engrafting CD5-transfected chronic leukemia B cells into SCID mice. Treatment of the animals with five daily injections of either allanxanthone C or macluraxanthone resulted in a significant prolongation of their survival as compared to control animals injected with the solvent alone p and p respectively . The same treatment of mice which were not xenografted induced no mortality. Conclusion These data show for the first time the in vivo antileukemic activities of two plant-derived xanthones and confirm their potential interest for CLL therapy. To the Editor Despite recent therapeutic advances with the combination of purine analogs alkylating agents and monoclonal antibodies chronic lymphocytic leukemia CLL remains an incurable disease 1-3 . It is characterized by the clonal expansion of a population of CD5 B lymphocytes and by the accumulation in the blood of leukemic cells that are quiescent but defective in their apoptotic program 2 4 . Thus CLL is a disease of proliferation as well as accumulation. Treatments targeting both dividing and apoptosis-deficient quiescent cells might therefore improve the CLL patients outcome 2-4 . A number of plant-derived .
